Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00682981 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Phase 1 study, sponsored by Gemin X.
- Completed
- Registry status
- Phase 1
- Development phase
- 218
- Enrollment target
NCT00682981 is a Phase 1 study that has completed, run by Gemin X. The registered enrollment target is 218 participants.
The verdict
NCT00682981, a Phase 1 study, has completed, sponsored by Gemin X.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 218 participants
- Enrollment target
Study Summary
The Phase I portion of this protocol will determine the best phase II dose and schedule of obatoclax with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. The Phase II portion will evaluate the response rate to this regimen.
Interventions
- DRUG Obatoclax
- DRUG Carboplatin/etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2008-05 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00682981
The ClinicalTrials.gov registry entry for NCT00682981 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gemin X, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Obatoclax is the first listed.
NCT00682981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00682981 about?
NCT00682981 is a clinical study titled "A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)". The Phase I portion of this protocol will determine the best phase II dose and schedule of obatoclax with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. The Phase II portion will evaluate the response rate to this regimen.
What is the current status of trial NCT00682981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 218 participants. The study started on 2008-05. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00682981?
The interventions under investigation include: Obatoclax (DRUG), Carboplatin/etoposide (DRUG).
Who is sponsoring clinical trial NCT00682981?
This trial is sponsored by Gemin X, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.